Deborah McWhinney - Fresenius Medical Member of the Supervisory Board

FMS Stock  USD 20.76  0.72  3.35%   

Executive

Ms. Deborah Doyle McWhinney was Independent Member of the Supervisory Board of Fresenius Medical Care AG Co. KGaA since May 12, 2016. She is Member of the Audit and Corporationrationrate Governance Committee at the Company. She serves at Lloyds Banking Group plc, Great Britain, Fluor Corporationrationration, U. S. and IHS Markit Ltd., Great Britain . since 2016.
Age 61
Tenure 8 years
Address Else-KrOener-Strasse 1, Bad Homburg, Germany, 61352
Phone49 6172 609 0
Webhttps://www.freseniusmedicalcare.com

Fresenius Medical Management Efficiency

The company has Return on Asset of 0.0273 % which means that on every $100 spent on assets, it made $0.0273 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0484 %, implying that it generated $0.0484 on every 100 dollars invested. Fresenius Medical's management efficiency ratios could be used to measure how well Fresenius Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 0.07 in 2024, whereas Return On Tangible Assets are likely to drop 0.03 in 2024. At this time, Fresenius Medical's Other Current Assets are comparatively stable compared to the past year. Intangible Assets is likely to gain to about 1.7 B in 2024, whereas Non Current Assets Total are likely to drop slightly above 13.8 B in 2024.
The company has 12.05 B in debt with debt to equity (D/E) ratio of 0.88, which is OK given its current industry classification. Fresenius Medical Care has a current ratio of 1.16, demonstrating that it is not liquid enough and may have problems paying out its financial commitments when the payables are due. Debt can assist Fresenius Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Fresenius Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Fresenius Medical Care sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Fresenius to invest in growth at high rates of return. When we think about Fresenius Medical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Lynette CPAPennant Group
47
Danielle BurkhalterSurgery Partners
39
Christine BentInnovAge Holding Corp
53
Angela JusticeSurgery Partners
45
Ernest FranklinTenet Healthcare
N/A
Kathleen JDHCA Holdings
60
Andrew PriceEncompass Health Corp
57
Jana DurfeeTenet Healthcare
N/A
Chad WassermanHCA Holdings
N/A
Bill PriestAcadia Healthcare
N/A
Gretchen HommrichAcadia Healthcare
N/A
Joseph IIIHCA Holdings
67
Cheryl LevyEncompass Health Corp
58
Karen SternerUniversal Health Services
N/A
John OGradyRamsay Health Care
N/A
Cara BabachicosInnovAge Holding Corp
N/A
Matthew KleinUniversal Health Services
N/A
Lyn KetelsenHCA Holdings
N/A
Matt HurayInnovAge Holding Corp
N/A
Isa DiazAcadia Healthcare
N/A
Michael NelsonUniversal Health Services
N/A
KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany. Fresenius Medical is traded on New York Stock Exchange in the United States. Fresenius Medical Care (FMS) is traded on New York Stock Exchange in USA. It is located in Else-KrOener-Strasse 1, Bad Homburg, Germany, 61352 and employs 119,845 people. Fresenius Medical is listed under Health Care Providers & Services category by Fama And French industry classification.

Management Performance

Fresenius Medical Care Leadership Team

Elected by the shareholders, the Fresenius Medical's board of directors comprises two types of representatives: Fresenius Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fresenius. The board's role is to monitor Fresenius Medical's management team and ensure that shareholders' interests are well served. Fresenius Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fresenius Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Oliver Maier, Senior Vice President of Investor Relations
Roberto Fuste, Member of the Management Board for Asia-Pacific
Walter Weisman, Member of the Supervisory Board
Michael Brosnan, CFO of Fresenius Medical Care Management AG and Member of the Management Board - Fresenius Medical Care Management AG
Pascale Witz, Independent Member of the Supervisory Board
GailSuzanne Brown, Senior Development
Katarzyna MazurHofsab, Management AG
Borries Muller, Senior Communications
FACHE MBA, CEO Board
Kent Wanzek, Member of the Management Board - Fresenius Medical Care Management AG and CEO of Global Manufacturing and Quality - Fresenius Medical Care Management AG
Joachim Weith, Senior Affairs
Deborah McWhinney, Member of the Supervisory Board
Robert Powell, Chairman Board
Franklin FACP, Global AG
Gregory Sorensen, Independent Member of the Supervisory Board
Dorothea Wenzel, Independent Member of the Supervisory Board
Martin Fischer, CFO AG
Glenn Slater, Senior Operations
Dieter Schenk, Vice Chairman of the Supervisory Board
Katarzyna MazurHofsaess, Member of the Management Board, Chief Executive Officer for Europe, Middle East and Africa (EMEA) Segment
Ronald Kuerbitz, Member of the Management Board - Fresenius Medical Care Management AG and CEO of Fresenius Medical Care North America - Fresenius Medical Care Management AG
Dominik Wehner, Member of the Management Board for Europe, Middle East and Africa
Gregor Zuend, Independent Member of the Supervisory Board
Rolf Classon, Independent Vice Chairman of the Supervisory Board
Helen Giza, Chief Financial Officer, Member of the Management Board, Chief Transformation Officer
Ben Lipps, Honorary Chairman
Gregor Zund, Member of the Supervisory Board
Bernd Fahrholz, Member of the Supervisory Board
Nwamaka MD, Head Operations
William Johnston, Independent Member of the Supervisory Board
Olaf Schermeier, CEO of Global RandD at Fresenius Medical Care Management AG and Member of the Management Board at Fresenius Medical Care Management AG
Dominik Heger, Head of Investor Relations & Corporate Communications
Frank Maddux, Member of the Management Board, Global Chief Medical Officer
William Valle, Member of the Management Board, Chief Executive Officer for the North America Segment
Rice Powell, Chairman of the Management Board, Chief Executive Officer
Harry Wit, Member of the Management Board, Chief Executive Officer for the Asia-Pacific Segment
Wolfgang Kummerle, Senior International
Carla Kriwet, CEO Care
Gerd Krick, Chairman of the Supervisory Board

Fresenius Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fresenius Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Fresenius Medical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Fresenius Medical's short interest history, or implied volatility extrapolated from Fresenius Medical options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Fresenius Medical Care is a strong investment it is important to analyze Fresenius Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fresenius Medical's future performance. For an informed investment choice regarding Fresenius Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fresenius Medical Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Fresenius Stock analysis

When running Fresenius Medical's price analysis, check to measure Fresenius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fresenius Medical is operating at the current time. Most of Fresenius Medical's value examination focuses on studying past and present price action to predict the probability of Fresenius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fresenius Medical's price. Additionally, you may evaluate how the addition of Fresenius Medical to your portfolios can decrease your overall portfolio volatility.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Commodity Directory
Find actively traded commodities issued by global exchanges
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Is Fresenius Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fresenius Medical. If investors know Fresenius will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fresenius Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.353
Dividend Share
1.19
Earnings Share
0.91
Revenue Per Share
33.1505
Quarterly Revenue Growth
(0)
The market value of Fresenius Medical Care is measured differently than its book value, which is the value of Fresenius that is recorded on the company's balance sheet. Investors also form their own opinion of Fresenius Medical's value that differs from its market value or its book value, called intrinsic value, which is Fresenius Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fresenius Medical's market value can be influenced by many factors that don't directly affect Fresenius Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fresenius Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fresenius Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fresenius Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.